- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT07809048
Deep Learning for Automatic Segmentation of Bone Sequestra on Orthopantomographs: A UNet-Based Approach (Deep Learning)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
Bone sequestration is the formation of a dead bone fragment demarcated from normal bone tissue, usually following dental extractions, delayed healing, chronic infection, or compromised blood supply. It is most frequently associated with osteomyelitis, an infectious process leading to bone inflammation. Osteomyelitis is mostly diagnosed based on clinical presentation with imaging and laboratory evidence but is established through bone biopsy and microbial culture.
Infection of the alveolar bone may be due to various reasons like dental caries, trauma, surgery, and local infection. The dental infections in the majority of instances have localized abscesses, but occasionally, the infection is disseminated, and osteomyelitis follows. Radiation therapy (RT), a standard head and neck cancer therapy, also can lead to osteoradionecrosis (ORN), a disease process in which irradiated bone becomes devitalized, open, and nonhealing. Another mechanism of bone sequestration is medication-related osteonecrosis of the jaw (MRONJ), a complication of antiresorptive and antiangiogenic therapy. First described in 2003 as bisphosphonate-related osteonecrosis of the jaw (BRONJ), the disease was later reclassified by the American Association of Oral and Maxillofacial Surgeons (AAOMS) in 2014 to include cases with non-bisphosphonate therapy, denosumab, and antiangiogenic agents. The medications, given chronically to treat osteoporosis and cancer-related bone disease, lead to interference of vascular supply and thus result in ischemia, hypoperfusion, and eventually bone death.
Although MRONJ is a rare complication, it significantly affects the quality of life of the patient by causing chronic bone exposure, pain, and functional disability. Bone sequestration is a significant problem in the context of all categories of bone disease, including osteomyelitis, ORN, and MRONJ. Pathogenesis, risk factors, and diagnostic criteria should be familiarized with to improve patient outcomes and minimize complications of bone necrosis.
Precise definition of bone sequestrum is essential for diagnosis, treatment planning, and surgical decision-making. Orthopantomography (OPG) or panoramic radiography is widely used in oral and maxillofacial radiology to assess bone disease, such as sequestrum formation. Manual segmentation of sequestrum in OPG is challenging because of anatomical structure superimposition, varying radiopacity, and subjective.
Artificial intelligence (AI) has rapidly expanded in the medical imaging field by providing automated and objective solutions to segmentation challenges. Solutions based on deep learning in the form of CNNs and U-Net-type architectures have been found to be high in accuracy to segment pathological structures from radiographic images. The techniques utilize large data sets to train to identify complex patterns and to differentiate between pathologic areas of bone and normal tissue, potentially improving the capacity to identify sequestrum on OPGs.
Although AI-based segmentation has been comprehensively explored in CT and MRI in most medical centers, it is comparatively less developed in the context of OPG imaging. Since OPG is more accessible and cheaper than cross-sectional imaging modalities, AI-based segmentation of OPGs has the potential to make diagnostic procedures and decision-making in dental and maxillofacial practice more efficient.Variable image quality, annotation challenges, and model generalizability across populations remain barriers that must be addressed before clinical deployment. This study presents an AI-based approach for automated sequestrum segmentation from OPG radiographs, describes the deep learning methodology employed, evaluates model performance, and discusses future clinical applications in dental radiology.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
Çiğli
-
Izmir, Çiğli, Turquie (Türkiye), 35640
- Izmir Katip Celebi University
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Patient with exposed bone over 8 weeks with a history of bisphosphonates or antiangiogenic drugs,
- Patient with a history of previous radiotherapy,
- Patients with necrotic exposed bone with or without a history of trauma
- Patients with osteomyelitis.
Exclusion Criteria:
- Patients with no clear vision of the borders of the sequestra,
- Panoramic images with artifacts in and around the lesion.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Deep Learning Segmentation
Délai: Up to 10 weeks
|
evaluated how artificial intelligence can identify the lesions on panoramic images
|
Up to 10 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- IRB No: 0206
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .